DK173033B1 - Farmaceutisk præparat med forlænget frigørelse og fremstilling deraf - Google Patents

Farmaceutisk præparat med forlænget frigørelse og fremstilling deraf Download PDF

Info

Publication number
DK173033B1
DK173033B1 DK198701549A DK154987A DK173033B1 DK 173033 B1 DK173033 B1 DK 173033B1 DK 198701549 A DK198701549 A DK 198701549A DK 154987 A DK154987 A DK 154987A DK 173033 B1 DK173033 B1 DK 173033B1
Authority
DK
Denmark
Prior art keywords
composition according
active substance
weight
composition
castor oil
Prior art date
Application number
DK198701549A
Other languages
Danish (da)
English (en)
Other versions
DK154987A (da
DK154987D0 (da
Inventor
Karl-Erik Lennart Falk
John Albert Sjoegren
Sven Morgan Hugosson
Adam Rosinski
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20364135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK173033(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of DK154987D0 publication Critical patent/DK154987D0/da
Publication of DK154987A publication Critical patent/DK154987A/da
Application granted granted Critical
Publication of DK173033B1 publication Critical patent/DK173033B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK198701549A 1986-04-11 1987-03-26 Farmaceutisk præparat med forlænget frigørelse og fremstilling deraf DK173033B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8601624 1986-04-11
SE8601624A SE8601624D0 (sv) 1986-04-11 1986-04-11 New pharmaceutical preparations

Publications (3)

Publication Number Publication Date
DK154987D0 DK154987D0 (da) 1987-03-26
DK154987A DK154987A (da) 1987-10-12
DK173033B1 true DK173033B1 (da) 1999-11-29

Family

ID=20364135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198701549A DK173033B1 (da) 1986-04-11 1987-03-26 Farmaceutisk præparat med forlænget frigørelse og fremstilling deraf

Country Status (34)

Country Link
US (1) US4803081A (ko)
EP (1) EP0249587B1 (ko)
JP (1) JPH0778016B2 (ko)
KR (2) KR870009720A (ko)
CN (1) CN1025150C (ko)
AT (1) ATE76288T1 (ko)
AU (1) AU602677B2 (ko)
CA (1) CA1304294C (ko)
CS (1) CS270560B2 (ko)
CY (1) CY1826A (ko)
DD (1) DD263231A5 (ko)
DE (1) DE3779183D1 (ko)
DK (1) DK173033B1 (ko)
DZ (1) DZ1067A1 (ko)
EG (1) EG18265A (ko)
ES (1) ES2031929T3 (ko)
FI (1) FI91826C (ko)
GR (1) GR3005286T3 (ko)
HK (1) HK26795A (ko)
HU (1) HU204699B (ko)
IE (1) IE59419B1 (ko)
IS (1) IS1553B (ko)
MY (1) MY101553A (ko)
NO (1) NO174795B (ko)
NZ (1) NZ219633A (ko)
PH (1) PH22494A (ko)
PL (1) PL265078A1 (ko)
PT (1) PT84663B (ko)
SE (1) SE8601624D0 (ko)
SG (1) SG4295G (ko)
SU (1) SU1743332A3 (ko)
UA (1) UA12336A (ko)
YU (1) YU47258B (ko)
ZA (1) ZA871911B (ko)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
RO112991B1 (ro) * 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
ES2168271T3 (es) 1992-09-25 2002-06-16 Novartis Ag Composiciones farmaceuticas que contienen ciclosporinas.
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
ES2229473T3 (es) 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
DE60128683T2 (de) * 2000-04-11 2008-01-24 Sankyo Co., Ltd. Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
WO2002056883A1 (en) * 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
CA2452871C (en) * 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
CN1596101A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
PL1915137T3 (pl) * 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP6025820B2 (ja) 2011-04-20 2016-11-16 フリースケール セミコンダクター インコーポレイテッド 増幅器及び関連する集積回路
CN104997750B (zh) * 2015-07-30 2018-03-20 杭州康恩贝制药有限公司 一种非洛地平缓释片及其制备方法
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
CN109200026B (zh) * 2017-07-03 2021-01-05 北京四环科宝制药有限公司 一种非洛地平缓释片及其制备方法
WO2019241519A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
JPS5495721A (en) * 1978-01-11 1979-07-28 Nippon Kayaku Co Ltd Nifedipine preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
JPS618A (ja) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk ニフエジピン含有製剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Also Published As

Publication number Publication date
FI871585A (fi) 1987-10-12
ATE76288T1 (de) 1992-06-15
ES2031929T3 (es) 1993-01-01
YU47258B (sh) 1995-01-31
EG18265A (en) 1992-12-30
SE8601624D0 (sv) 1986-04-11
IS3214A7 (is) 1987-10-12
US4803081A (en) 1989-02-07
HU204699B (en) 1992-02-28
AU7004387A (en) 1987-10-15
FI871585A0 (fi) 1987-04-10
FI91826B (fi) 1994-05-13
CN1025150C (zh) 1994-06-29
DK154987A (da) 1987-10-12
PT84663A (en) 1987-05-01
NO871199L (no) 1987-10-12
KR870009720A (ko) 1987-11-30
IE59419B1 (en) 1994-02-23
CS270560B2 (en) 1990-07-12
DZ1067A1 (fr) 2004-09-13
NO174795B (no) 1994-04-05
FI91826C (fi) 1994-08-25
PH22494A (en) 1988-09-12
SG4295G (en) 1995-06-16
YU40787A (sh) 1992-09-07
DE3779183D1 (de) 1992-06-25
CA1304294C (en) 1992-06-30
SU1743332A3 (ru) 1992-06-23
CY1826A (en) 1995-12-01
NZ219633A (en) 1989-11-28
AU602677B2 (en) 1990-10-25
ZA871911B (en) 1987-12-30
PL265078A1 (en) 1988-07-21
UA12336A (uk) 1996-12-25
GR3005286T3 (ko) 1993-05-24
IE870925L (en) 1987-10-11
JPH0778016B2 (ja) 1995-08-23
NO174795C (ko) 1994-07-13
NO871199D0 (no) 1987-03-23
CS258787A2 (en) 1989-11-14
IS1553B (is) 1994-08-10
EP0249587B1 (en) 1992-05-20
EP0249587A1 (en) 1987-12-16
HK26795A (en) 1995-03-10
PT84663B (pt) 1989-11-30
HUT43786A (en) 1987-12-28
MY101553A (en) 1991-12-17
DK154987D0 (da) 1987-03-26
KR950002147B1 (ko) 1995-03-14
KR890001521A (ko) 1989-03-27
CN87102758A (zh) 1987-10-21
DD263231A5 (de) 1988-12-28
JPS62242613A (ja) 1987-10-23

Similar Documents

Publication Publication Date Title
DK173033B1 (da) Farmaceutisk præparat med forlænget frigørelse og fremstilling deraf
JP2619936B2 (ja) 新規な薬学的製剤およびその製法
RU2161956C2 (ru) Трехфазная фармацевтическая форма с постоянным и регулируемым высвобождением аморфного активного ингредиента для одноразового применения в сутки
RU2163803C2 (ru) Фармацевтические композиции, содержащие дарифенацин
JP2010519200A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
CA2920758A1 (en) Pharmaceutical compositions of fingolimod
EP0284849A1 (en) Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture
JP2003504392A (ja) 新規医薬製剤
HRP920630A2 (en) New pharmaceutical preparations having extended delivery
KR20240102908A (ko) 아픽사반을 포함하는 서방성 정제
EP1560568A1 (en) Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
KR100540734B1 (ko) 펠로디핀의 방출 제어형 제제
MXPA01007814A (es) Formulacion farmaceutica de libekracion prolongada independiente al ph

Legal Events

Date Code Title Description
PHB Application deemed withdrawn due to non-payment or other reasons
B1 Patent granted (law 1993)
PUP Patent expired